Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Beam Therapeutics Inc (NASDAQ: BEAM) was $30.79 for the day, up 1.18% from the previous closing price of $30.43. In other words, the price has increased by $1.18 from its previous closing price. On the day, 1.83 million shares were traded.
Ratios:
Our analysis of BEAM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.69 and its Current Ratio is at 5.69. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.
On November 06, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $27 to $39.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 18 ’25 when Cavanagh Bethany J sold 6,287 shares for $35.00 per share. The transaction valued at 220,045 led to the insider holds 37,527 shares of the business.
Bellon Christine sold 10,000 shares of BEAM for $340,000 on Feb 14 ’25. The Chief Legal Officer now owns 102,968 shares after completing the transaction at $34.00 per share. On Feb 14 ’25, another insider, CHRISTINE BELLON, who serves as the Officer of the company, bought 10,000 shares for $34.00 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.29 while its Price-to-Book (P/B) ratio in mrq is 3.21.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $20.84. The 50-Day Moving Average of the stock is 12.69%, while the 200-Day Moving Average is calculated to be 20.20%.
Shares Statistics:
A total of 82.56M shares are outstanding, with a floating share count of 72.91M. Insiders hold about 11.96% of the company’s shares, while institutions hold 84.26% stake in the company.
Earnings Estimates
Currently, 16.0 analysts are dedicated to thoroughly evaluating and rating the performance of Beam Therapeutics Inc (BEAM) in the stock market.The consensus estimate for the next quarter is -$1.2, with high estimates of -$0.9 and low estimates of -$1.41.
Analysts are recommending an EPS of between -$4.36 and -$5.03 for the fiscal current year, implying an average EPS of -$4.68. EPS for the following year is -$4.71, with 14.0 analysts recommending between -$3.34 and -$5.48.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 13 analysts. It ranges from a high estimate of $42M to a low estimate of $5M. As of the current estimate, Beam Therapeutics Inc’s year-ago sales were $316.19MFor the next quarter, 13 analysts are estimating revenue of $15.15M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $6M.
A total of 15 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $75M, while the lowest revenue estimate was $38.4M, resulting in an average revenue estimate of $51.42M. In the same quarter a year ago, actual revenue was $377.71MBased on 14 analysts’ estimates, the company’s revenue will be $58.9M in the next fiscal year. The high estimate is $110M and the low estimate is $26M.
